3Helix’s CHP technology has the unparalleled ability to seek out and bind to areas of molecular collagen damage and can be safely used locally or systemically. In addition to an attractive safety profile and tunable targeting ability, CHP’s can be easily linked to any cargo and provide targeted binding capabilities and the unique ability to extend binding duration beyond what is possible for any competing technology. CHP targeting technology can be used with both small molecules and biologics to safely and accurately target areas of inflammation, fibrosis, injury, or damage and help augment duration of effect.
Our technology has already proven effective for targeted payload delivery in a variety of conditions including hypervascular conditions in the back of the eye like nAMD, NASH (now MASH), Multiple Myeloma and beyond.
Join the revolution in targeted diagnosis and treatment of conditions that affect collagen.